| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
Nephrology Research and Training Center, Division of Nephrology, Departments of Medicine and Physiology, University of Alabama at Birmingham, Birmingham, Alabama.
Correspondence to: Dr. Janos Peti-Peterdi, University of Alabama at Birmingham, 865 Sparks Center, 1530 3rd Avenue South, Birmingham, AL 35294. Phone: 205-934-5783; Fax: 205-934-1147; E-mail: petjan{at}uab.edu
| Abstract |
|---|
|
|
|---|
= 25.2 ± 3.7 mM) and initial rate (
5 fold) of change in [Na+]i to increased luminal [NaCl]. AngII when added to the bath had similar stimulatory effects; however, AngII was much more effective from the lumen. Thus, AngII significantly increased the apical entry of Na+ in the CCD. To determine if this apical entry step occurred via the epithelial Na+ channel (ENaC), studies were performed using the specific ENaC blocker, benzamil hydrochloride (10-6 M). When added to the perfusate, benzamil almost completely inhibited the elevations in [Na+]i to increased luminal [NaCl] in both the presence and absence of AngII. These results suggest that AngII directly stimulates Na+ channel activity in the CCD. AT1 receptor blockade with candesartan or losartan (10-6 M) prevented the stimulatory effects of AngII. Regulation of ENaC activity by AngII may play an important role in distal Na+ reabsorption in health and disease. | Introduction |
|---|
|
|
|---|
Although the effects of AngII on proximal tubular transport have been extensively examined, much less is known about the effects of AngII on tubular transport by more distal nephron segments. Studies have reported that AngII can alter transport in distal tubular segments (7,8), cortical collecting ducts (9), and macula densa cells (10,11). In the distal tubule and cortical collecting duct, AngII may stimulate Na:H exchange (79). Also of potential importance is the findings by Wang and Giebisch (12) that the effects of AngII to stimulate volume reabsorption in the late distal tubule not only involves the acid base transporters (Na:H exchange and NaHCO3 cotransport) but may act via Na+ channels. They found that the effects of AngII on volume reabsorption were inhibited by amiloride, an agent that blocks Na+ channels. Although amiloride also blocks Na:H exchangers, the isoform expressed at the apical membranes is quite amiloride-resistant. Thus, it is important to establish if AngII directly acts on Na+ channels in the distal nephron/collecting duct segment.
Why is it important to study the effects of AngII and its blockade in distal nephron segments? Although the proximal tubule is responsible for reabsorbing the bulk of the glomerular filtrate, it is the distal nephron segments that are ultimately responsible for the rate of urine formation and its composition. This is also the nephron site that is responsible for BP-induced changes in urine flow and Na+ excretion (pressure natriuresis and diuresis). In older studies by Hall et al. (13,14), they demonstrated in a one-kidney dog model that intrarenal infusions of AngII can cause hypertension by shifting the pressure natriuresis curve to the right, i.e., it required a higher BP to excrete Na+ compared with control non-AngII-infused kidneys. This was despite equivalent rates of glomerular filtration in the control and AngII-infused groups. Thus, AngII can cause hypertension through its effects to promote Na+ reabsorption most likely in the collecting duct.
Elements of a paracrine RAS along the distal nephron have recently been described (15). Angiotensinogen is synthesized by proximal tubule cells and secreted into tubular fluid, and then uncleaved angiotensinogen transits through the entire nephron and can be found in final urine (15,16). Renin is synthesized and secreted by connecting tubule cells (15). The existence of endopeptidases and carboxypeptidase in distal tubular fluid (17) may also have a potential role in the generation of angiotensins from AngI. Immunohistochemical studies (18) have additionally established the existence of AT1 receptors at both the apical and basolateral membranes in distal nephron segments including the collecting duct. It is also well established that a significant amount of AngII is secreted into the tubular fluid (1921). These elements of a tubular RAS may be involved in the coordinated regulation of sodium reabsorption by the distal nephron.
The purpose of these studies was to develop a model in which to study ENaC activity in the collecting duct. When this was accomplished, we sought to determine if AngII could alter Na+ transport via this apical channel, and finally we evaluated the effects of AT1 receptor blockade on ENaC activity.
| Materials and Methods |
|---|
|
|
|---|
[Na+]i Measurement
[Na+]i of CCD cells was measured using photometry-based fluorescence microscopy (Photon Technology International, Lawrenceville, NJ) and sodium-binding benzofuran isophthalate (SBFI) (Teflabs, Austin, TX) with similar techniques as described for Ca2+ and pHi measurements (11,22). SBFI fluorescence was measured at an emission wavelength of 510 nm in response to excitation wavelengths of 340 and 380 nm. Cells were loaded with the dye by adding SBFI-AM (20 µM) dissolved in dimethyl sulfoxide (DMSO) to the luminal perfusate. The nonionic surfactant, Pluronic F-127 was added (1 mg/ml) to DMSO to facilitate loading that required approximately 15 min, then the SBFI-AM in the lumen was removed. After approximately 15-min incubation of the tubule with the control perfusion solution, fluorescence intensities for both wavelengths stabilized at constant level. SBFI fluorescence ratios (340/380 nm) were converted into [Na+]i values after permeabilizing cell membranes on both sides of the tubules with 10 µM nigericin + monensin and equilibrating [Na+]i with ambient [Na+] in a stepwise manner between 0 to 150 mM.
We used measurements of [Na+]i as a reflection of Na+ transport across the apical membrane. To assess the activity of ENaC alone, the basolateral membrane was permeabilized to Na+ with monensin, and bath [NaCl] was reduced to zero. Luminal Na+ ([NaCl]L) was then increased from 25 to 150 mM. EnaC-specific activity was assessed by applying 10-6 M of the ENaC blocker benzamil, a concentration that does not affect Na+:H+ exchange. Measurements consisted of the resting [Na+]i under control conditions (isosmotic 25 mM luminal and 0 mM bath [NaCl]), and the magnitude (
Na+i) and initial rate (
Na+i/
t) of increases in [Na+]i when [NaCl]L was increased from 25 to 150 mM using a PTI software. Experiments were performed in the presence/absence of luminal benzamil or the Na:H exchanger blocker HOE694 (from Hans-Jochen Lang, Aventis Pharma, Frankfurt, Germany), luminal or basolateral AngII (both from Sigma Chemical Co., St. Louis, MO) administered with/without the AT1 receptor blocker candesartan (generous gift from Peter Morsing, AstraZeneca, Molndal, Sweden) or losartan (generous gift from Leslie Koch, Merck, Rahway, NJ). Final DMSO concentrations were below 0.1%.
Statistical Analyses
Data are expressed as mean ± SE. Statistical significance was tested using ANOVA. Significance was defined as P < 0.05.
| Results |
|---|
|
|
|---|
Na+i = 0.7 ± 0.4 mM; n = 5; P < 0.05). The specific Na:H exchange blocker HOE694 added to the luminal perfusate (1 mM) caused no significant changes in control Na+i dynamics (
Na+i = 7.72 ± 2.6 mM; n = 7) (Figure 1A). These findings strongly suggest that, in our experimental model, [NaCl]L-dependent increases in CCD Na+i are due to apical ENaC activity rather than Na:H exchange.
|
Na+i = 25.2 ± 3.7 mM) and initial rate (
Na+i/
t
5-fold) of increases in [Na+]i when [NaCl]L was increased from 25 to 150 mM. In some experiments, low doses of luminal AngII had similar stimulatory effects on the rabbit CCD [Na+]i dynamics. Added to the luminal perfusate, 10-12 M AngII caused
2.5-fold increase in the initial rate of increases in [Na+]i (
Na+i/
t) when [NaCl]L was increased from 25 to 150 mM. AngII, added to the bath was also stimulatory but smaller in scale (Figure 2, left panels). The specific ENaC blocker benzamil added to the luminal perfusate (10-6 M) significantly decreased baseline [Na+]i by 19.2 mM (n = 5) and almost completely inhibited the [NaCl]Ldependent increase in [Na+]i when coadministered with luminal AngII. Similar effects were observed with bath AngII (Figure 2). These findings clearly suggest that the effects of AngII on [Na+]i dynamics were due to the stimulation of ENaC at the apical membrane.
|
2.5-fold increase in both
Na+i and the initial rate of increases in [Na+]i (
Na+i/
t) when [NaCl]L was increased from 25 to 150 mM, compared with control. Thus luminal AngII, in the 10-9 to 10-12 M range, increases the apical membrane permeability to Na+ in the CCD in both mouse and rabbit.
|
Na+i, and
Na+i/
t). Luminal candesartan or losartan alone had no effect on any of these parameters. These data suggest that the stimulatory effects of AngII were mediated via AT1 receptors.
|
| Discussion |
|---|
|
|
|---|
Baseline [Na+]i under control conditions was stable around 20 to 25 mM and was sensitive to benzamil in both the presence and absence of AngII (Figure 2). This suggests a significant contribution of ENaC activity and hence apical Na+-transport in maintaining baseline [Na+]i. More importantly, the 150 mM [NaCl]Linduced increase in both
Na+i and
Na+i/
t were almost completely abolished in the presence of benzamil, indicating that the majority of apical Na+-entry during this maneuver was mediated by ENaC.
AngII significantly increased benzamil-sensitive elevations in [Na+]i in response to 150 mM [NaCl]L, suggesting stimulation of ENaC activity. Addition of AngII to either tubular perfusate or bath produced stimulatory effects, indicating that AngII acts through luminal and basolateral AngII receptors to stimulate the apically located ENaC in CCD segments. However, AngII was much more effective from the lumen. By measuring the initial rate of the high [NaCl]L-induced increase in [Na+]i, luminal AngII caused an approximately fivefold stimulation of ENaC activity (Figure 2). Of particular importance, AngII was also effective in low concentrations (10-12 M). This suggests that AngII, in the low physiologic concentration range of 10-9 to 10-12 M, is capable of increasing the apical membrane permeability to Na+ in the CCD. In terms of the physiologic importance of this paracrine loop, the mouse model will in the long run offer many more opportunities in genetically engineered animals.
Stimulatory effects of AngII were prevented by the coadministration of the AT1 receptor antagonist candesartan or losartan, suggesting AT1 receptor mediation. The reason that we performed additional experiments with losartan was that candesartan, particularly from the bath (data not shown), produced a slight increase in parameters of [Na+]i dynamics. However, this slight stimulation by candesartan did not occur with luminal administration (Figure 4) and was completely absent with losartan.
We found that AngII significantly enhanced apical Na+ entry in CCD obtained from mice on a normal Na+ diet. These preliminary studies open the possibilities for future studies in genetically engineered mice in which components of the RAS system have been either eliminated or augmented.
In summary, these studies measured [Na+]i as a reflection of Na+ transport across the apical membrane of CCD. Whether AngII stimulates net transepithelial Na+ reabsorption in this important nephron segment needs to be further investigated. Direct stimulation of ENaC by AngII is consistent with the presence of a paracrine RAS in the distal tubule. Elements of this system are regulated by dietary sodium intake (15); therefore, locally produced AngII through ENaC activity may tonically enhance Na+-reabsorption in the CCD depending on Na+ intake. This distal tubular RAS-AngII-ENaC system may play an important role in disease mechanisms leading to hypertension, and this site may be an important therapeutic target for RAS inhibitors and receptor blockers.
| Acknowledgments |
|---|
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
J. Peti-Peterdi, J. J. Kang, and I. Toma Activation of the renal renin-angiotensin system in diabetes--new concepts Nephrol. Dial. Transplant., October 1, 2008; 23(10): 3047 - 3049. [Full Text] [PDF] |
||||
![]() |
D. Zhao and L. G. Navar Acute Angiotensin II Infusions Elicit Pressure Natriuresis in Mice and Reduce Distal Fractional Sodium Reabsorption Hypertension, July 1, 2008; 52(1): 137 - 142. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Kang, I. Toma, A. Sipos, E. J. Meer, S. L. Vargas, and J. Peti-Peterdi The Collecting Duct Is the Major Source of Prorenin in Diabetes Hypertension, June 1, 2008; 51(6): 1597 - 1604. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Prieto-Carrasquero, F. T. Botros, J. Pagan, H. Kobori, D. M. Seth, D. E. Casarini, and L. G. Navar Collecting Duct Renin Is Upregulated in Both Kidneys of 2-Kidney, 1-Clip Goldblatt Hypertensive Rats Hypertension, June 1, 2008; 51(6): 1590 - 1596. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. A. Drummond, S. C. Grifoni, and N. L. Jernigan A New Trick for an Old Dogma: ENaC Proteins as Mechanotransducers in Vascular Smooth Muscle Physiology, February 1, 2008; 23(1): 23 - 31. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Pech, W. Zheng, T. D. Pham, J. W. Verlander, and S. M. Wall Angiotensin II Activates H+-ATPase in Type A Intercalated Cells J. Am. Soc. Nephrol., January 1, 2008; 19(1): 84 - 91. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Fenton and M. A. Knepper Mouse Models and the Urinary Concentrating Mechanism in the New Millennium Physiol Rev, October 1, 2007; 87(4): 1083 - 1112. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. H. Kim, V. Pech, K. B. Spencer, W. H. Beierwaltes, L. A. Everett, E. D. Green, W. Shin, J. W. Verlander, R. L. Sutliff, and S. M. Wall Reduced ENaC protein abundance contributes to the lower blood pressure observed in pendrin-null mice Am J Physiol Renal Physiol, October 1, 2007; 293(4): F1314 - F1324. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Kobori, M. Nangaku, L. G. Navar, and A. Nishiyama The Intrarenal Renin-Angiotensin System: From Physiology to the Pathobiology of Hypertension and Kidney Disease Pharmacol. Rev., September 1, 2007; 59(3): 251 - 287. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. W. Verlander The thiazide-sensitive NaCl cotransporter: a new target for acute regulation of salt and water transport by angiotensin II Am J Physiol Renal Physiol, September 1, 2007; 293(3): F660 - F661. [Full Text] [PDF] |
||||
![]() |
V. Pech, Y. H. Kim, A. M. Weinstein, L. A. Everett, T. D. Pham, and S. M. Wall Angiotensin II increases chloride absorption in the cortical collecting duct in mice through a pendrin-dependent mechanism Am J Physiol Renal Physiol, March 1, 2007; 292(3): F914 - F920. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Eskild-Jensen, K. Thomsen, C. Rungo, L. S. Ferreira, L. F. Paulsen, Y. F. Rawashdeh, J. R. Nyengaard, S. Nielsen, J. C. Djurhuus, and J. Frokiaer Glomerular and tubular function during AT1 receptor blockade in pigs with neonatal induced partial ureteropelvic obstruction Am J Physiol Renal Physiol, March 1, 2007; 292(3): F921 - F929. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-M. Lalouel and A. Rohrwasser Genetic Susceptibility to Essential Hypertension: Insight From Angiotensinogen Hypertension, March 1, 2007; 49(3): 597 - 603. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.D. Crowley, S.B. Gurley, M.J. Herrera, P. Ruiz, R. Griffiths, A.P. Kumar, H.-S. Kim, O. Smithies, T.H. Le, T.M. Coffman, et al. Role of Renal Angiotensin II Type 1 Receptors in the Genesis of Hypertension: Guyton Revisited: Angiotensin II Causes Hypertension and Cardiac Hypertrophy through Its Receptors in the Kidney. Proc Natl Acad Sci U S A 103: 17985-17990, 2006 J. Am. Soc. Nephrol., February 1, 2007; 18(2): 356 - 363. [Full Text] [PDF] |
||||
![]() |
Y.-J. Lee, I.-K. Song, K.-J. Jang, J. Nielsen, J. Frokiaer, S. Nielsen, and T.-H. Kwon Increased AQP2 targeting in primary cultured IMCD cells in response to angiotensin II through AT1 receptor Am J Physiol Renal Physiol, January 1, 2007; 292(1): F340 - F350. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. D. Crowley, S. B. Gurley, M. J. Herrera, P. Ruiz, R. Griffiths, A. P. Kumar, H.-S. Kim, O. Smithies, T. H. Le, and T. M. Coffman Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney PNAS, November 21, 2006; 103(47): 17985 - 17990. [Abstract] [Full Text] [PDF] |
||||
![]() |
D.-F. Guo, I. Chenier, J. L. Lavoie, J. S.D. Chan, P. Hamet, J. Tremblay, X. M. Chen, D. H. Wang, and T. Inagami Development of Hypertension and Kidney Hypertrophy in Transgenic Mice Overexpressing ARAP1 Gene in the Kidney Hypertension, September 1, 2006; 48(3): 453 - 459. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-P. Ma and D. C. Eaton Acute Regulation of Epithelial Sodium Channel by Anionic Phospholipids J. Am. Soc. Nephrol., November 1, 2005; 16(11): 3182 - 3187. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Prieto-Carrasquero, H. Kobori, Y. Ozawa, A. Gutierrez, D. Seth, and L. G. Navar AT1 receptor-mediated enhancement of collecting duct renin in angiotensin II-dependent hypertensive rats Am J Physiol Renal Physiol, September 1, 2005; 289(3): F632 - F637. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Loghman-Adham, C. E. Soto, T. Inagami, and C. Sotelo-Avila Expression of Components of the Renin-angiotensin System in Autosomal Recessive Polycystic Kidney Disease J. Histochem. Cytochem., August 1, 2005; 53(8): 979 - 988. [Abstract] [Full Text] [PDF] |
||||
![]() |
T.-H. Kwon, J. Nielsen, M. A. Knepper, J. Frokiaer, and S. Nielsen Angiotensin II AT1 receptor blockade decreases vasopressin-induced water reabsorption and AQP2 levels in NaCl-restricted rats Am J Physiol Renal Physiol, April 1, 2005; 288(4): F673 - F684. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Valles, J. Wysocki, M. R. Salabat, I. Cokic, M. Ye, M. S. LaPointe, and D. Batlle Angiotensin II Increases H+-ATPase B1 Subunit Expression in Medullary Collecting Ducts Hypertension, April 1, 2005; 45(4): 818 - 823. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Narumiya, S. Sasaki, N. Kuwahara, H. Irie, T. Kusaba, H. Kameyama, K. Tamagaki, T. Hatta, K. Takeda, and H. Matsubara HMG-CoA reductase inhibitors up-regulate anti-aging klotho mRNA via RhoA inactivation in IMCD3 cells Cardiovasc Res, November 1, 2004; 64(2): 331 - 336. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Meneton, J. Loffing, and D. G. Warnock Sodium and potassium handling by the aldosterone-sensitive distal nephron: the pivotal role of the distal and connecting tubule Am J Physiol Renal Physiol, October 1, 2004; 287(4): F593 - F601. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Prieto-Carrasquero, L. M. Harrison-Bernard, H. Kobori, Y. Ozawa, K. S. Hering-Smith, L. L. Hamm, and L. G. Navar Enhancement of Collecting Duct Renin in Angiotensin II-Dependent Hypertensive Rats Hypertension, August 1, 2004; 44(2): 223 - 229. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. W. Kim, W. Wang, J. Nielsen, J. Praetorius, T.-H. Kwon, M. A. Knepper, J. Frokiaer, and S. Nielsen Increased expression and apical targeting of renal ENaC subunits in puromycin aminonucleoside-induced nephrotic syndrome in rats Am J Physiol Renal Physiol, May 1, 2004; 286(5): F922 - F935. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Lavoie, K. D. Lake-Bruse, and C. D. Sigmund Increased blood pressure in transgenic mice expressing both human renin and angiotensinogen in the renal proximal tubule Am J Physiol Renal Physiol, May 1, 2004; 286(5): F965 - F971. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Kobori, M. C. Prieto-Carrasquero, Y. Ozawa, and L. G. Navar AT1 Receptor Mediated Augmentation of Intrarenal Angiotensinogen in Angiotensin II-Dependent Hypertension Hypertension, May 1, 2004; 43(5): 1126 - 1132. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Nielsen, T.-H. Kwon, J. Praetorius, Y.-H. Kim, J. Frokiaer, M. A. Knepper, and S. Nielsen Segment-specific ENaC downregulation in kidney of rats with lithium-induced NDI Am J Physiol Renal Physiol, December 1, 2003; 285(6): F1198 - F1209. [Abstract] [Full Text] |
||||
![]() |
P. Komlosi, A. L. Fuson, A. Fintha, J. Peti-Peterdi, L. Rosivall, D. G. Warnock, and P. D. Bell Angiotensin I Conversion to Angiotensin II Stimulates Cortical Collecting Duct Sodium Transport Hypertension, August 1, 2003; 42(2): 195 - 199. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Yuan, M. Liang, Z. Yang, E. Rute, N. Taylor, M. Olivier, and A. W. Cowley Jr. Gene expression reveals vulnerability to oxidative stress and interstitial fibrosis of renal outer medulla to nonhypertensive elevations of ANG II Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2003; 284(5): R1219 - R1230. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. T. Beutler, S. Masilamani, S. Turban, J. Nielsen, H. L. Brooks, S. Ageloff, R. A. Fenton, R. K. Packer, and M. A. Knepper Long-Term Regulation of ENaC Expression in Kidney by Angiotensin II Hypertension, May 1, 2003; 41(5): 1143 - 1150. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Loffing and B. Kaissling Sodium and calcium transport pathways along the mammalian distal nephron: from rabbit to human Am J Physiol Renal Physiol, April 1, 2003; 284(4): F628 - F643. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||